Jul 15, 2025
GT Medical Technologies Completes Final Close of Company's Oversubscribed $53 Million Series D Equity Financing to Advance Commercial Treatment for Patients with Operable Brain Tumors
Jun 30, 2025
GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
Jun 10, 2025
GT Medical Technologies Names James Leech Chief Financial and Strategy Officer
Jun 03, 2025
GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
May 20, 2025
GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
May 06, 2025
GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
Apr 30, 2025
GT Medical Technologies Welcomes Second GammaTile® Center of Excellence Designation
Nov 13, 2024
GT Medical Technologies Achieves Two Clinical Milestones with GammaTile® to Help Treat Brain Tumors
Sep 12, 2024
GT Medical Technologies, Inc. Secures $35 Million Venture Loan Facility from Horizon Technology Finance
Jun 20, 2024
GT Medical Technologies, Inc. Appoints Two Industry Medical Device Veterans to Key Leadership Positions
May 01, 2024
GT Medical Technologies, Inc. and Theragenics Corporation Forge Distribution Partnership for Cesium-131
Apr 15, 2024
GT Medical Technologies, Inc. Completes Strategic Acquisition of Radioactive Seed Assets from Perspective Therapeutics, Inc.
Apr 09, 2024
GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors
Jan 12, 2021
Expanded Use of Innovative Brain Tumor Treatment Exemplified in GT Medical Technologies' 2020 GammaTile® Therapy ELITE Member Roster